极度早产婴儿的专利性动脉管道:关于当前诊断和治疗选择的最新情况
Kimberly Fernandez Trahan1, Elaine L Shelton1, Maria Gillam-Krakauer1
1Division of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center, 2200 Children's Way, DOT, 11111, Nashville, TN 37232 USA.
Current treatment options in cardiovascular medicine
|July 25, 2025
概括
标准化专利动脉管道 (PDA) 治疗需要解决知识差距. 最近的进展,如针对性新生儿心声学 (TnECHO) 和新疗法,显示了个性化婴儿护理的前景.
科学领域:
- 新生儿心脏病学 新生儿心脏病学
- 儿科药理学 儿科药理学
- 医疗技术 医疗技术 医学技术
背景情况:
- 由于血液动力学意义 (hsPDA) 的不同定义和有限的长期结果数据,专利性动脉管 (PDA) 治疗缺乏标准化.
- 管理方法的差异仍然存在,影响新生儿的临床决策.
研究的目的:
- 审查新生儿期当前的PDA治疗策略.
- 识别阻碍标准化的知识差距,并讨论最近的进展.
- 探索针对性和个性化的PDA管理的未来方向.
主要方法:
- 关于PDA管理的最新临床试验和文献的审查.
- 分析新兴的诊断工具,如针对性新生儿心声学 (TnECHO).
- 对药理学 (例如,乙氨基) 和非药理学干预措施的评估.
主要成果:
- 在最近的试验中,PDA的早期与预期治疗并没有显示出改善的结果.
- 在TnECHO的帮助下,可以及时进行积极的干预,并取得积极的结果.
- 乙氨基的使用正在增加,即使是在非常早产的婴儿 (<24周).
- 进步包括皮肤透导管封闭和理解管道基因表达.
结论:
- 针对性,个性化的PDA治疗正变得可以通过增加TnECHO的使用,澄清过导管闭合范围,以及更好地了解导管遗传学来实现.
- 对遗传/分子因素和药物/液体平衡影响的进一步研究至关重要.
- 开发创新疗法以促进管道关闭仍然是必要的.
相关概念视频
01:25Aortic Regurgitation III: Medical Management
44
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
44
01:30Cardiomyopathy II: Dilated Cardiomyopathy
23
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
23
01:26Mitral Stenosis III: Medical Management
23
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
23
01:22Heart Failure VI: Adjunct Therapies
28
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
28
01:29Cardiomyopathy V: Interprofessional Care
34
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
34
01:25Mitral Regurgitation III: Medical Management
31
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
31